Atara Biotherapeutics, Inc. (ATRA)
Oxford Ledge is still expanding full research coverage of ATRA. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Atara develops off-the-shelf T-cell immunotherapies for cancer and autoimmune disease, with its lead product approved in Europe and under U.S. review.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Departure/election of directors or officers 2026-06-26
- 8-K Departure/election of directors or officers; Shareholder vote results 2026-06-12
- 10-Q Quarterly financial report (unaudited) 2026-05-12
- 8-K Financial statements and exhibits 2026-05-12
- 8-K Other material event 2026-05-07
Source: SEC EDGAR.
Annual results
5 years of annual figures for ATRA, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $120.8M | $32.7M | $2.57 |
| 2024 | $128.9M | -$85.4M | -$11.41 |
| 2023 | $8.6M | -$276.1M | -$65.19 |
| 2022 | $63.6M | -$228.3M | -$2.24 |
| 2021 | — | -$340.1M | -$3.63 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for ATRA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ATRA in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.